DNA vs BIIB

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 19, 2026

DNA

44.7
AI Score
VS
DNA Wins

BIIB

38.5
AI Score

Investment Advisor Scores

DNA

45score
Recommendation
HOLD

BIIB

39score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DNA BIIB Winner
Revenue 39.63M 2.48B BIIB
Net Income -129.30M 319.50M BIIB
Net Margin -326.3% 12.9% BIIB
ROE -30.8% 1.7% BIIB
ROA -13.1% 1.1% BIIB
Total Assets 990.05M 29.48B BIIB
Current Ratio 4.57 3.06 DNA
Free Cash Flow -95.51M 594.30M BIIB

Relative Price Performance (Last 90 Days)

DNA 1M: -4.1% · 3M: +31.9% BIIB 1M: +11.1% · 3M: +25.6%

Current Technical Phase

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 46.3 · Price: $9.83

BIIB

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (4.9% over 20 days), RSI 72

RSI (14): 71.5 · Price: $251.40

Fundamentals Snapshot

Metric DNA BIIB
Market Cap — —
Forward P/E -3.4 15.4
Trailing P/E — 42.8
Revenue (TTM) — —
Revenue Growth -0.5% 0.0%
Gross Margin 0.7% 0.8%
Operating Margin -2.8% 0.3%
EPS -5.06 5.63
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DNA is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.